1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Colinz Laboratories Limited

Colinz Laboratories Limited

COLINZ.BO
Colinz Laboratories LimitedIN flagBombay Stock Exchange
69.36
INR
+2.86
- -
174.72MMarket Cap
Colinz Laboratories Limited
COLINZ.BO
(Bombay Stock Exchange)

Recent

price

69.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
12.34
12.48
14.35
15.3
16.7
17.15
17.97
16.71
17.09
16.78
16.63
13.35
15.21
28.83
27.88
25.9
23.12
Revenue per Share
0.19
0.16
0.24
0.17
0.15
0.21
0.21
0.31
0.5
0.27
0.29
0.45
0.74
1.82
1.93
1.97
1.95
Basic EPS, GAAP
0.89
1.72
0.44
0.32
1.44
0.21
1.28
0.09
0.73
0.25
1.17
4.34
0.94
1.62
4.1
-6.81
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
9.02
9.18
9.36
9.34
10.04
9.33
9.74
9.9
10.31
10.67
10.96
11.31
12.12
20.1
21.71
23.69
- -
Book Value per Share
12.94
13.19
13.43
13.33
14.27
13.4
13.94
14.27
14.63
14.97
14.96
15.8
16.77
32.79
35.49
37.58
- -
Tangible Book Value per Share
5
5
5
5
4
5
5
5
5
5
5
5
5
2
3
3
3
Basic Weighted Avg Shares
56
57
66
72
74
79
81
76
79
77
76
62
70
72
70
65
58
Sales/Revenue/Turnover
4.05
3.72
3.64
4.18
2.84
1.99
2.09
1.89
1.75
1.76
1.42
2.28
5.52
7.04
5.87
5.57
4.51
Operating Margin (%)
3
3
3
3
3
3
3
3
2
2
2
2
2
1
1
1
2
Depreciation Expense
1
1
1
1
1
1
1
1
2
1
1
2
3
5
5
5
5
Net Income, GAAP
- -
7.13
- -
50.1
47.43
33.66
37.54
- -
- -
21.84
25.91
15.33
29.36
23.74
25.16
19.83
17.23
Effective Tax Rate (%)
1.5
1.28
1.67
1.11
0.9
1.22
1.17
1.85
2.93
1.59
1.72
3.37
4.87
6.31
6.92
7.61
8.45
Profit Margin (%)
44
31
29
32
30
42
30
32
34
39
42
47
54
59
66
69
- -
Working Capital
31
28
24
23
19
23
16
14
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
59
60
62
63
63
62
63
65
68
68
68
73
77
81
89
95
- -
Total Equity
- -
2.2
- -
1.75
1.32
1.25
1.22
- -
- -
1.4
1.07
1.5
3.24
4.6
3.43
2.97
- -
Return on Invested Capital (%)
- -
3.05
- -
2.71
1.71
2.67
2.49
- -
- -
3.69
3.29
4.84
6.41
8.7
9.1
8.38
14.83
Return on Capital (%)
4.11
1.75
2.6
1.84
1.5
2.21
2.18
3.17
4.97
2.53
2.64
4.06
6.3
8.57
9.3
8.68
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
7
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
3
- -
Market Capitalization
112
104
135

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
92
- -
Cash, Cash Equivalents & STI
- -
74
- -
Accounts Receivable, Net
- -
8
- -
Inventories
- -
10
- -
Total Current Liabilities
- -
20
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
7
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.43%
6.75%
5.87%
Free Cash Flow
153.32%
15.79%
-265.79%
Net Income, GAAP
23.6%
33.1%
2.03%
Sales/Revenue/Turnover
-1.54%
-2.41%
-7.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19
18
17
16
70
2025
17
19
15
15
65
2026
16
14
14
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.48
0.49
0.42
- -
1.93
2025
0.54
0.62
0.21
- -
1.97
2026
0.47
0.56
0.33
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Grupo International Inc. (GRPI)
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF)
Zenlabs Ethica Limited (ZENLABS.BO)
Rising Biosciences, Inc. (RBII)
EGF Theramed Health Corp. (EVAHF)
Medexus Pharmaceuticals Inc. (MDP.TO)
Business
Colinz Laboratories Limited operates as a pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical formulations, injectables, and specialty chemicals. The company’s core product portfolio includes generic pharmaceutical drugs, formulations for human use, and contract manufacturing services catering to the global pharmaceutical industry. It serves multiple therapeutic segments and offers its products and services to healthcare providers, pharmaceutical companies, and distributors across India and international markets. Founded in 1991, Colinz Laboratories Limited is headquartered in Mumbai, India. In recent developments, Colinz Laboratories Limited has focused on strategic business expansions by enhancing its manufacturing capabilities and entering new markets through partnerships and collaborations with other pharmaceutical entities. The company has launched new product lines to diversify its portfolio and strengthen its presence in key therapeutic categories. It has also undertaken operational upgrades to meet stringent regulatory requirements and improve overall production efficiency. These initiatives are part of its continued efforts to solidify its position in the pharmaceutical manufacturing sector and expand its geographic footprint. Colinz Laboratories operates primarily within the pharmaceutical manufacturing industry, specializing in APIs and finished formulations. Its customer base includes hospitals, healthcare professionals, pharmaceutical distributors, and multinational companies. The company has subsidiaries and maintains compliance with regulatory frameworks in the countries it operates. It leverages advanced technology and quality standards to support pharmaceutical innovation and supply chain reliability. Overall, Colinz Laboratories Limited distinguishes itself through comprehensive pharmaceutical product offerings, strategic operational improvements over the last two years, and consistent service to diverse healthcare markets across India and abroad.